Literature DB >> 11976813

Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.

Klaus Tatsch1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11976813     DOI： 10.1007/s00259-002-0814-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

Review 1.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease.

Authors:  T Brücke; S Djamshidian; G Bencsits; W Pirker; S Asenbaum; I Podreka
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

Review 2.  Neurochemical and neuroreceptor imaging with PET in Parkinson's disease.

Authors:  A J Stoessl
Journal:  Adv Neurol       Date:  2001

Review 3.  Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease.

Authors:  D J Brooks
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 4.  Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.

Authors:  J Booij; G Tissingh; A Winogrodzka; E A van Royen
Journal:  Eur J Nucl Med       Date:  1999-02

Review 5.  Imaging the vesicular monoamine transporter.

Authors:  K A Frey; R A Koeppe; M R Kilbourn
Journal:  Adv Neurol       Date:  2001

Review 6.  Imaging of the dopaminergic system in parkinsonism with SPET.

Authors:  K Tatsch
Journal:  Nucl Med Commun       Date:  2001-07       Impact factor: 1.690

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

Authors:  T Ishikawa; V Dhawan; K Kazumata; T Chaly; F Mandel; J Neumeyer; C Margouleff; B Babchyck; I Zanzi; D Eidelberg
Journal:  J Nucl Med       Date:  1996-11       Impact factor: 10.057

9.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

10.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Authors:  C S Lee; A Samii; V Sossi; T J Ruth; M Schulzer; J E Holden; J Wudel; P K Pal; R de la Fuente-Fernandez; D B Calne; A J Stoessl
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422
  10 in total
  8 in total

1.  Iterative reconstruction or filtered backprojection for semi-quantitative assessment of dopamine D₂ receptor SPECT studies?

Authors:  Walter Koch; Christine Suessmair; Klaus Tatsch; Gabriele Pöpperl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

2.  Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia.

Authors:  Yoshiaki Furukawa; Stephen J Kish
Journal:  Brain       Date:  2014-11-21       Impact factor: 13.501

3.  European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis.

Authors:  Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Gitte M Knudsen; Pierre Malick Koulibaly; Flavio Nobili; Marco Pagani; Osama Sabri; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-16       Impact factor: 9.236

4.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

5.  Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging.

Authors:  Deborah Pareto; Albert Cot; Javier Pavía; Carles Falcón; Ignacio Juvells; Francisco Lomeña; Domènec Ros
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

6.  Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease.

Authors:  Wen-Sheng Huang; Meei-Shyuan Lee; Jiann-Chyun Lin; Cheng-Yu Chen; Yu-Wen Yang; Shinn-Zong Lin; Shiaw-Pyng Wey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

7.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

8.  99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable.

Authors:  Skye Hsin-Hsien Yeh; Chi-Jung Tsai; Tsung-Hsun Yu; Yung-Hsiao Chiang; Shinn-Zong Lin; Nan-Jing Peng; Wen-Sheng Huang
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.